GD0039: Began Phase II trials

GlycoDesign Inc. (TSE:GD), Toronto, Ontario
Product: GD0039

Read the full 75 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE